摘要
目的:探究胸腺肽联合左氧氟沙星对肺结核患者免疫功能、相关血清指标以及预后质量的影响。方法:选取2016年1月—2018年3月我院收治的肺结核患者200例,根据治疗方案的不同分为研究组与对照组,各100例。对照组接受常规抗结核方案治疗,在此基础上,研究组加施左氧氟沙星(400 mg,qd)联合胸腺肽肠溶片(5 mg,tid)治疗。比较两组治疗效果、免疫功能指标、相关血清因子水平及不良反应。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,研究组相关血清因子肿瘤坏死因子(TNF)-α、降钙素元(PCT)、干扰素(IFN)-γ、白细胞介素(IL)-15低于对照组,差异有统计学意义(P<0.05);研究组CD3^+、CD4^+高于对照组,CD8^+低于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:胸腺肽联合左氧氟沙星治疗肺结核的疗效显著,可有效提高患者的免疫功能,纠正机体炎症状态,且安全性高。
Objective:To investigate the effect of thymosin combined with levofloxacin on immune function,related serum indexes and prognosis quality in patients with pulmonary tuberculosis.Methods:200 patients with pulmonary tuberculosis admitted to our hospital from January 2016 to March 2018 were selected and divided into a study group and a control group according to different treatment regimens,100 cases each.The patients in the control group received conventional anti-tuberculosis regimen.On this basis,the patients in the study group were treated with levofloxacin(400 mg,qd)combined with thymosin enteric-coated tablets(5 mg,tid).The therapeutic effect,immune function indexes,related serum factor levels and adverse reactions were compared between the two groups.Results:The total effective rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of related serum factors such as tumor necrosis factor(TNF)-α,calcitonin(PCT),interferon(IFN)-γand interleukin(IL)-15 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of CD3+and CD4+in the study group were higher than those in the control group,while the level of CD8+was lower than that in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Thymosin combined with levofloxacin is significantly effective in the treatment of pulmonary tuberculosis,which can effectively improve the immune function of the patients and correct body’s inflammatory state,and has high safety.
作者
张亚平
岳峰
Zhang Ya-ping;Yue Feng(Department of Infectious Diseases,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang Henan 471000,China)
出处
《中国合理用药探索》
CAS
2019年第11期35-38,共4页
Chinese Journal of Rational Drug Use
作者简介
张亚平,女,硕士,医师。研究方向:肺结核、病毒性肝炎、肝硬化等。E-mail:zhangyaping77640@163.com;通讯作者:岳峰,男,主任医师。研究方向:肺结核、病毒性肝炎、肝硬化等。E-mail:zhangyaping77640@163.com
